Ainos (AIMD)
NASDAQ:AIMD
Want to see AIMD full AI Analyst Report?
AIMD Stock Chart & Stats
$2.28
$0.28(14.00%)
At close: 4:00 PM EST
$2.28
$0.28(14.00%)
Day’s Range― - ―
52-Week Range$1.26 - $4.50
Previous CloseN/A
Volume448.92K
Average Volume (3M)78.00K
Market Cap
$13.37M
Enterprise Value$18.29M
Total Cash (Recent Filing)$417.35K
Total Debt (Recent Filing)$11.00M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding7,266,011
10 Day Avg. Volume93,591
30 Day Avg. Volume77,998
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.93
Price to Sales (P/S)56.41
P/FCF Ratio-1.51
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue147.30
Enterprise Value/Gross Profit177.72
Enterprise Value/Ebitda-1.97
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary AI Nose PlatformThe company’s AI Nose platform represents a durable, platform-based business model: a core sensing technology applicable to diagnostics and drug development. Platform scalability and multiple use cases (point-of-care, monitoring, drug programs) support structural growth if adoption and regulatory paths progress.
High Product Gross Margins ObservedAn 83% gross margin in 2025 indicates attractive unit economics for the company’s sensing/diagnostic outputs, implying products can be highly profitable at scale. If fixed operating costs are reduced or revenue scales, gross margin strength provides a structural path to improved operating leverage over the medium term.
Positive Equity (not Insolvent)Equity remaining positive gives the company structural survivability and potential to raise incremental capital without immediate insolvency risk. Maintaining a non-negative capital base preserves strategic optionality to fund R&D, pursue partnerships, or execute a remediation plan versus a company with zero or negative equity.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow (~-$4.6M in 2025) is a structural weakness: it necessitates frequent external funding, risks dilution, and constrains investment. Until the company achieves consistent positive operating cash flow, financing dependencies will limit long-term financial flexibility and strategy execution.
Rising Leverage And Shrinking EquityLeverage has increased materially (debt-to-equity ~1.45), reflecting shrinking equity and greater creditor exposure. Higher leverage reduces resilience to revenue shocks, raises interest and covenant risk, and narrows strategic choices; it makes financing more costly and increases probability of distress if losses continue.
Large Operating Losses Vs RevenueNet margin around -119% and persistent operating losses show the cost base is far larger than current revenue. This structural mismatch means profitability is unlikely without significant cost restructuring or sustained revenue scale-up, challenging the company’s path to self-sustaining operations over the medium term.
Ainos News
AIMD FAQ
What was Ainos’s price range in the past 12 months?
Ainos lowest stock price was $1.26 and its highest was $4.50 in the past 12 months.
What is Ainos’s market cap?
Ainos’s market cap is $13.37M.
When is Ainos’s upcoming earnings report date?
Ainos’s upcoming earnings report date is May 18, 2026 which is in 18 days.
How were Ainos’s earnings last quarter?
Ainos released its earnings results on Mar 30, 2026. The company reported -$0.853 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.853.
Is Ainos overvalued?
According to Wall Street analysts Ainos’s price is currently Overvalued.
Does Ainos pay dividends?
Ainos does not currently pay dividends.
What is Ainos’s EPS estimate?
Ainos’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ainos have?
Ainos has 7,266,011 shares outstanding.
What happened to Ainos’s price movement after its last earnings report?
Ainos reported an EPS of -$0.853 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.878%.
Which hedge fund is a major shareholder of Ainos?
Currently, no hedge funds are holding shares in AIMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ainos
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Soligenix
―
Chemomab Therapeutics
―
―
FibroBiologics, Inc.
―
Ownership Overview
52.74% Insiders
0.44% Mutual Funds
0.94% Other Institutional Investors
45.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---